CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 794 enrolled
Drug / intervention
MC2-01 cream +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03308799
NCT03308799Phase 3Completed
CompareCT.gov

A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects With Mild-to-Moderate Psoriasis Vulgaris

MC2 Therapeutics·interventional·Posted Oct 13, 2017·Updated Dec 9, 2024

In Brief

A Phase 3 clinical trial evaluating MC2-01 cream, Cal/BDP combination, and 1 other intervention for Psoriasis Vulgaris. Completed, enrolled 794 participants across 3 sites.

Detailed Summary

This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedOct 13, 2017
Enrollment StartOct 3, 2017
Primary CompletionJun 8, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.7 years ago

Interventions

MC2-01 creamdrug

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream

Cal/BDP combinationdrug

calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%

Cream vehicledrug

Vehicle Cream